People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.